Literature DB >> 6288292

Epstein-Barr virus (EBV)--lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells.

P C Patel, J Menezes.   

Abstract

We investigated the influence of the Epstein-Barr virus (EBV) replication cycle on natural killing (NK) activity and antibody-dependent cellular cytotoxicity (ADCC) against EBV-infected cells. Peripheral blood lymphocytes from healthy EBV-seropositive and -seronegative donors were separated on Ficoll-Hypaque gradients and used as effector cells in the standard 51Cr release assay to measure NK and ADCC. EBV-genome positive RAJI and DAUDI cells superinfected with either the non-transforming P3HR-1 EBV or the transforming B95-8 EBV were used as targets. The results obtained show that most normal individuals have ADCC and NK activity against P3HR-1 EBV-infected RAJI cells. Both the cytotoxic activities increased with the proportional increase in effector/target (E/T) ratios, assay incubation time, dose of the infecting virus and the time of pre-infection with EBV. Moreover, the data obtained indicate that different immune mechanisms are effective at different stages of the virus replication cycle. During the early stages of virus replication, EBV-superinfected cells are more susceptible to ADCC than to NK, whereas in later stages the susceptibility to NK is increased significantly and appears to play a more dominant role. The nature of the target cells or the strain of EBV used to superinfect these targets did not influence their susceptibility to ADCC and NK activity; however some quantitative differences were found. Using metabolic inhibitors such as cytosine arabinoside, phosphonoacetic acid, actinomycin D, cycloheximide and puromycin, it was found that new DNA synthesis is not essential but some RNA and protein synthesis is necessary, late in the viral cycle, for the superinfected cells to become susceptible to NK and ADCC.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288292      PMCID: PMC1536597     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Enhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis.

Authors:  L M Hutt; Y T Huang; H E Dascomb; J S Pagano
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

2.  Comparative studies on the induction of virus-associated nuclear antigen and early antigen by lymphocyte-transforming (B95-8) and nontransforming (P3HR-1) strains of Epstein-Barr virus.

Authors:  J Menezes; P Patel; H Dussault; A E Bourkas
Journal:  Intervirology       Date:  1978       Impact factor: 1.763

Review 3.  In vitro and in vivo investigations on antibody-dependent cellular cytotoxicity.

Authors:  G R Pearson
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

4.  Expression of HL-A antigens on the surface of cultured human lymphoid cells: effect of inhibitors of protein and nucleic acid synthesis.

Authors:  S Ferrone; B C Del Villano; M A Pellegrino; R A Lerner; R A Reisfeld
Journal:  Tissue Antigens       Date:  1972

5.  Detection of virus-specific antigens in EB-(P3HR1) virus-superinfected Raji cells by immunoprecipitation.

Authors:  W W Bodemer; W C Summers; J C Niederman
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

6.  Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins.

Authors:  B C Strnad; R H Neubauer; H Rabin; R A Mazur
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

7.  Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis.

Authors:  I Royston; J L Sullivan; P O Periman; E Perlin
Journal:  N Engl J Med       Date:  1975-12-04       Impact factor: 91.245

8.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

9.  Identification of target antigen for antibody-dependent cellular cytotoxicity on cells carrying Epstein-Barr virus genome.

Authors:  K Takaki; M Harada; T Sairenji; Y Hinuma
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

10.  Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.

Authors:  B Blazar; M Patarroyo; E Klein; G Klein
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

View more
  5 in total

1.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  Increased sensitivity to natural killing in Raji cells is due to effector recognition of molecules appearing on target cell membranes following EBV cycle induction.

Authors:  B A Blazar; J Fitzgerald; L Sutton; M Strome
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

3.  Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.

Authors:  Chen S Tan; Joshua Ghofrani; Emma Geiger; Igor J Koralnik; Stephanie Jost
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

4.  Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.

Authors:  S K Sundar; J Bergeron; J Menezes
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

5.  Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines.

Authors:  P C Patel; G Dorval; J Menezes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.